What is semaglutide?
Semaglutide is the active ingredient in several prescription medicines, including Ozempic, Wegovy and Rybelsus. It activates the GLP-1 receptor, helping regulate blood sugar and appetite. Large randomized trials have shown benefits for weight and, in particular populations, cardiovascular, kidney and liver outcomes.
The product matters. A weekly injection and a daily tablet can contain the same molecule while having different formulations, doses, evidence and approved uses. The findings below are about those specific products and populations, not a promise that every person taking semaglutide will receive every benefit.
Which products are approved for what?
These are the U.S. indications checked on November 9, 2026. Authorization and availability elsewhere need a local check.
- Ozempic injection: blood-sugar control in adults with type 2 diabetes; reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; and reduction of sustained kidney-function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Injection label.
- Ozempic tablets and Rybelsus tablets: blood-sugar control in adults with type 2 diabetes, plus reduction of major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk. The label says these formulations are not substitutable milligram for milligram. It does not give them the injection's kidney indication. Tablet label.
- Wegovy injection: weight management in adults with obesity, adults with overweight plus at least one weight-related condition, and adolescents aged 12 and older with obesity; cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity; and accelerated approval for noncirrhotic MASH with moderate to advanced fibrosis, stages F2 to F3, in adults.
- Wegovy tablets: weight management in adults with obesity, or adults with overweight plus at least one weight-related condition; and cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity. The tablet does not carry the injection's adolescent or MASH indication. Wegovy label.
Wegovy HD, the 7.2 mg weekly injection, is an adult weight-management option in the current label. That higher dose is not the labeled MASH or cardiovascular maintenance regimen. Product choice and switching require the prescriber's instructions.
How much weight did the trials show people losing?
In STEP 1, 1,961 adults without diabetes received lifestyle support plus weekly semaglutide 2.4 mg or placebo. At 68 weeks, average weight loss was 14.9% versus 2.4%. Participants also reported better physical functioning. Gastrointestinal effects caused treatment discontinuation in 4.5% versus 0.8%.
Two newer trials tested different formulations. OASIS 4 randomized 307 adults without diabetes to daily oral semaglutide 25 mg or placebo. Average weight loss at week 64 was 13.6% versus 2.2%; gastrointestinal events occurred in 74.0% versus 42.2%. This was not a direct tablet-versus-injection trial.
In STEP UP, 1,407 adults with obesity and no diabetes received weekly 7.2 mg, 2.4 mg or placebo. At 72 weeks, average losses were 18.7%, 15.6% and 3.9%. The higher dose produced more weight loss but also more gastrointestinal events and dysesthesia, or altered skin sensations. Dysesthesia occurred in 22.9%, 6.0% and 0.5%, respectively. A higher average effect comes with a different tolerability tradeoff.
Does the heart benefit go beyond weight loss?
Trials have measured actual cardiovascular events. SELECT enrolled 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. Over about 40 months of follow-up, cardiovascular death, nonfatal heart attack or nonfatal stroke occurred in 6.5% on weekly semaglutide 2.4 mg versus 8.0% on placebo. The hazard ratio was 0.80, often described as a 20% relative reduction. The observed absolute difference was 1.5 percentage points. Adverse events led to permanent treatment discontinuation in 16.6% versus 8.2%.
For type 2 diabetes, SUSTAIN-6 found fewer major cardiovascular events with the injection, while diabetic-retinopathy complications were more frequent. The earlier oral PIONEER 6 trial established cardiovascular noninferiority, not a statistically established reduction in its primary event outcome.
The later SOUL trial provided stronger oral evidence: among 9,650 adults with type 2 diabetes and cardiovascular disease, chronic kidney disease or both, major cardiovascular events occurred in 12.0% on oral semaglutide versus 13.8% on placebo over about four years. The hazard ratio was 0.86. Its confirmatory secondary outcomes, including major kidney events, did not differ significantly.
What did the kidney trial establish?
The FLOW trial randomized 3,533 adults with type 2 diabetes and chronic kidney disease to weekly semaglutide 1 mg or placebo. Its combined outcome included kidney failure, a sustained large fall in kidney function, or kidney-related or cardiovascular death. Events occurred in 331 of 1,767 semaglutide participants and 410 of 1,766 placebo participants, about 18.7% versus 23.2%. The hazard ratio was 0.76.
FLOW stopped early after a planned interim analysis, with median follow-up of 3.4 years. Serious adverse events were less frequent with semaglutide. This is substantial evidence for the studied diabetes-and-kidney-disease population. It does not mean any semaglutide product treats every cause of kidney disease.
What changed for MASH, and where are the limits?
MASH is fatty liver disease with inflammation and injury; fibrosis means scarring. In the ESSENCE trial, 1,197 adults with biopsy-confirmed MASH and F2 or F3 fibrosis were randomized. The published 72-week interim analysis covered the first 800. MASH resolved without worsening fibrosis in 62.9% on weekly semaglutide 2.4 mg versus 34.3% on placebo. Fibrosis improved without worsening MASH in 36.8% versus 22.4%. Bodily pain scores did not differ significantly, and gastrointestinal effects were more common.
These biopsy findings support Wegovy injection's accelerated approval. They do not yet establish fewer liver failures, transplants or deaths; the longer ESSENCE follow-up is assessing clinical outcomes. In a separate 71-person trial with compensated cirrhosis, semaglutide did not significantly improve fibrosis or resolve steatohepatitis at 48 weeks. Results in earlier fibrosis should not be transferred to cirrhosis.
What happens after treatment stops?
In the STEP 1 extension, 327 participants were followed after both study medication and structured lifestyle support ended. One year later, the former semaglutide group had regained roughly two-thirds of its previous weight loss, while still averaging below its starting weight. This was a selected, exploratory follow-up group.
That finding makes ongoing care worth discussing from the start. It does not show that regain is a failure of willpower, or prove that tapering, protein intake or exercise alone will prevent it. The studies described here do not establish a universal stopping plan.
What risks deserve a proper conversation?
Nausea, vomiting, diarrhea and constipation are common, but the safety discussion should not stop there. Current prescribing information also covers pancreatitis, gallbladder disease, dehydration-related kidney injury, severe gastrointestinal reactions and retinopathy complications. Low blood sugar is a particular concern with insulin or sulfonylureas. Severe gastroparesis is a reason the labels do not recommend use. Planned anesthesia or deep sedation should be disclosed because delayed stomach emptying can create an aspiration risk.
The boxed thyroid warning comes from C-cell tumors in rodents; whether semaglutide causes these tumors in humans remains unknown. Personal or family history of medullary thyroid carcinoma, MEN2 and prior serious hypersensitivity are contraindications. Pregnancy plans, other medicines and existing eye disease need an individualized review.
On November 9, 2026, FDA required labeling changes for GLP-1 medicines concerning a potential increased risk of NAION, a rare optic-nerve condition that can cause permanent vision loss. This is a new safety communication, separate from diabetic retinopathy. Sudden painless vision loss or other new visual disturbances require prompt medical attention.
Safety reviews can also remove suspected risks. In January 2026, FDA requested removal of the suicidal-behavior and ideation warning after its review did not identify an increased risk with GLP-1 medicines. That finding does not remove the other precautions.
What should be clear before considering it?
Start with the actual goal: glucose control, weight management, cardiovascular risk, kidney disease or a confirmed liver diagnosis. Ask which product has evidence for that goal, what benefit is realistic, how tolerability and nutrition will be monitored, and what the longer-term plan involves.
A compounded product is not an FDA-approved version of Ozempic or Wegovy. FDA reports dosing errors and quality concerns with unapproved products and states that semaglutide sodium and acetate are different active ingredients from the one in approved medicines. A label saying “semaglutide” is not enough to establish equivalence.
Where the evidence applies
Weight management
Injection and oral trials show substantial average weight loss, with different doses and tolerability.
Heart and kidneys
Event reductions are demonstrated in defined populations; the product and indication matter.
Liver disease
MASH biopsy findings support accelerated approval for the injection in noncirrhotic F2/F3 disease.
Continuing questions
Long-term liver outcomes, individual tolerability and maintaining benefits after withdrawal still need attention.
Related study records are searchable on our Science page. The selected original studies and current regulatory sources used here are linked below.
Questions people ask
Are Ozempic, Rybelsus and Wegovy interchangeable?
No. They contain semaglutide but have different formulations, doses and approved indications. Current U.S. labeling includes Ozempic injections and tablets, Rybelsus tablets, and Wegovy injections and tablets. The Ozempic/Rybelsus tablet label explicitly says the two tablet formulations are not substitutable milligram for milligram. Switching needs product-specific prescribing instructions.
Does every semaglutide product have heart, kidney and liver indications?
No. U.S. labels assign these uses to particular products and populations. Ozempic injection has the diabetes-and-chronic-kidney-disease indication. Wegovy injection has accelerated approval for noncirrhotic MASH with F2 or F3 fibrosis. Oral products have cardiovascular indications, but those do not automatically include the injection-specific kidney or liver uses.
Does stopping mean the weight will come back?
Weight regain was common in the STEP 1 extension. After semaglutide and structured lifestyle support stopped, the former semaglutide group regained about two-thirds of its prior loss over a year. Individual outcomes vary. This follow-up did not establish that tapering or lifestyle changes alone prevent regain.
What is the new eye warning?
On November 9, 2026, FDA required GLP-1 drug labeling changes about a potential increased risk of non-arteritic anterior ischemic optic neuropathy, or NAION. It is rare but can cause permanent vision loss. Sudden painless vision loss or other new visual disturbances need prompt medical attention. This is distinct from the existing diabetic-retinopathy precaution.
What to take away
- Semaglutide has substantial trial evidence, but formulations and approved uses differ.
- Weight, cardiovascular and kidney benefits have been measured in specific populations, with real adverse effects and discontinuations.
- Wegovy injection's MASH approval is based on biopsy improvements; clinical liver outcomes are still being studied.
- Weight regain after withdrawal is common. These trials do not establish a universal stopping or tapering plan.
- Current safety discussions should include the November 9, 2026 FDA notice on potential NAION risk.
The evidence
Selected original studies, trial records and regulatory sources checked November 9, 2026. Study doses describe the research and are not instructions for use.
This article is for educational purposes only and is not medical advice, a diagnosis, or a treatment recommendation. Evidence and approvals apply to the products and populations described. Any treatment decision should be made with a qualified physician. Individual results vary.